Skip to main content

Arbutus Biopharma Corp

corporate_fare Company Profile

Arbutus Biopharma Corp

ABUS·NASDAQ·Life Sciences·CIK 0001447028

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The company is developing imdusiran (AB-729), a proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, a proprietary oral PD-L1 inhibitor, both for the treatment of chronic hepatitis B (cHBV). Arbutus is involved in ongoing litigation against Pfizer Inc. and BioNTech SE for their use of its patented lipid nanoparticle (LNP) technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines. A claim construction ruling was issued in September 2025. On March 3, 2026, Arbutus, along with Genevant Sciences GmbH and its parent, entered into a settlement agreement with Moderna, Inc. and its affiliates to resolve all patent infringement litigation and patent revocation proceedings. Under this agreement, Moderna will make an aggregate $950.0 million noncontingent lump sum payment to Arbutus and Genevant on or before July 8, 2026. Moderna is also obligated to pay an additional aggregate contingent lump sum payment of $1.3 billion upon a ruling favorable to Arbutus and Genevant in a limited appeal related to 28 U.S.C. §1498. Arbutus is entitled to receive 20% of the noncontingent settlement payment, after deduction of litigation costs, under its license with Genevant. As of the date of this annual report, Arbutus owns approximately 16% of the outstanding common equity of Genevant. The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026, following receipt of its portion of the noncontingent settlement payment.

Arbutus Biopharma Corp (NASDAQ:ABUS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ABUS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for ABUS spans 8-K, SC TO-I/A, SC TO-I, 10-Q.

Recent high-impact activity:

  • Arbutus Posts $59.1M Q3 Profit on Genevant Dividend, Expands Pfizer/BioNTech Patent Suits
  • Arbutus Swings to $59.1M Third-Quarter Profit
  • FDA Lifts Clinical Hold on Arbutus's AB-101 Oral PD-L1 Inhibitor IND
  • FDA Lifts Clinical Hold on Arbutus's Oral PD-L1 Inhibitor AB-101
  • Arbutus Completes $230M Dutch Auction Tender Offer at $5.00/Share, Retiring 23% of Shares

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$14.08M
Net Income
-$33.5M
Diluted EPS
-$0.17
Op. Cash Flow
-$39.64M
Free Cash Flow
-$39.64M
Operating Income
-$38.16M
Cash & Equivalents
$18.01M
Debt / Equity
0.00×
Net Margin
-237.9%
Shares Outstanding
192.53M sh
Source: 10-K · filed 2026-03-23 · accession 0001447028-26-000017

Short Interest & Short Volume

9.14 days to cover

FINRA reported short interest of 19,888,395 shares in ABUS as of the October 30, 2026 settlement, a 19.0% decrease from the prior period — about 9.1 days to cover at its recent average daily volume. On November 20, 2026, 54.4% of ABUS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)19,888,395 shares as of October 30, 2026
Change vs prior period▼ 19.0%
Days to cover9.14 at avg daily volume of 2,176,284
Daily short volume (FINRA facilities)54.4% of 1,155,608 shares on November 20, 2026
5-day average short volume61.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$3.98 -1.00% today
52-week range · as of 2026-11-10 $3.5 – $5.45
Market cap
$616.24M
Volume
3M (1.2× avg)
3-mo avg 2.6M
Live data · 2026-11-21 11:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABUS - Latest Insights

ABUS
Nov 10, 2026, 7:31 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.98 info
Change: +$0.270 (+7%) info
Market Cap: $616.237M info
ABUS
Nov 10, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.98 info
Change: +$0.270 (+7%) info
Market Cap: $616.237M info
ABUS
Oct 22, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $3.98 info
Change: -$0.270 (-6%) info
Market Cap: $616.237M info
ABUS
Oct 22, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.24
Real-time Price: $3.98 info
Change: -$0.2597 (-6%) info
Market Cap: $616.237M info
ABUS
Sep 30, 2026, 7:35 AM EDT
Filing Type: SC TO-I/A
Importance Score:
7
Updated Sep 30, 12:58 PM ET — Arbutus completed the tender offer, buying back 46 million shares at $5.00 each and retiring about 23% of outstanding stock.
Price at Filing: $4.66
Real-time Price: $3.98 info
Change: -$0.6828 (-15%) info
Market Cap: $616.237M info
ABUS
Aug 24, 2026, 8:24 AM EDT
Filing Type: SC TO-I
Importance Score:
7
Price at Filing: $5.21
Real-time Price: $3.98 info
Change: -$1.23 (-24%) info
Market Cap: $616.237M info
ABUS
Aug 21, 2026, 10:16 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $3.98 info
Change: -$1.22 (-23%) info
Market Cap: $616.237M info
ABUS
Aug 21, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.27
Real-time Price: $3.98 info
Change: -$1.29 (-24%) info
Market Cap: $616.237M info
ABUS
Aug 12, 2026, 7:31 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.49
Real-time Price: $3.98 info
Change: -$0.510 (-11%) info
Market Cap: $616.237M info
ABUS
Aug 12, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.52
Real-time Price: $3.98 info
Change: -$0.5397 (-12%) info
Market Cap: $616.237M info
ABUS
Aug 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $3.98 info
Change: -$0.520 (-12%) info
Market Cap: $616.237M info
ABUS
Jul 16, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $3.98 info
Change: -$0.590 (-13%) info
Market Cap: $616.237M info
ABUS
May 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.64
Real-time Price: $3.98 info
Change: -$0.660 (-14%) info
Market Cap: $616.237M info
ABUS
May 13, 2026, 7:31 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.43
Real-time Price: $3.98 info
Change: -$0.450 (-10%) info
Market Cap: $616.237M info
ABUS
May 13, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.43
Real-time Price: $3.98 info
Change: -$0.450 (-10%) info
Market Cap: $616.237M info
ABUS
Apr 28, 2026, 5:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.15
Real-time Price: $3.98 info
Change: -$0.170 (-4%) info
Market Cap: $616.237M info
ABUS
Apr 15, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.45
Real-time Price: $3.98 info
Change: -$0.470 (-11%) info
Market Cap: $616.237M info
ABUS
Apr 15, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.41
Real-time Price: $3.98 info
Change: -$0.430 (-10%) info
Market Cap: $616.237M info
ABUS
Apr 14, 2026, 5:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $3.98 info
Change: -$0.370 (-9%) info
Market Cap: $616.237M info
ABUS
Apr 13, 2026, 7:56 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.31
Real-time Price: $3.98 info
Change: -$0.3304 (-8%) info
Market Cap: $616.237M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets